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Abstract
Background: The major rate-limiting enzyme for de novo cholesterol synthesis is 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMGCR). HMGCR is sterically inhibited by statins, the most commonly prescribed drugs for
the prevention of cardiovascular events. Alternative splicing of HMGCR has been implicated in the control of
cholesterol homeostasis. The aim of this study was to identify novel alternatively spliced variants of HMGCR with
potential physiological importance.
Results: Bioinformatic analyses predicted three novel HMGCR transcripts containing an alternative exon 1
(HMGCR-1b, -1c, -1d) compared with the canonical transcript (HMGCR-1a). The open reading frame of the HMGCR-1b
transcript potentially encodes 20 additional amino acids at the N-terminus, compared with HMGCR-1a. Reverse
transcription quantitative polymerase chain reaction (RT-qPCR) was used to examine the mRNA levels of HMGCR in
different tissues; HMGCR-1a was the most highly expressed variant in most tissues, with the exception of the skin,
esophagus, and uterine cervix, in which HMGCR-1b was the most highly expressed transcript. Atorvastatin treatment
of HepG2 cells resulted in increased HMGCR-1b mRNA levels, but unaltered proximal promoter activity compared to
untreated cells. In contrast, HMGCR-1c showed a more restricted transcription pattern, but was also induced by
atorvastatin treatment.
Conclusions: The gene encoding HMGCR uses alternative, mutually exclusive exon 1 sequences. This contributes to
an increased complexity of HMGCR transcripts. Further studies are needed to investigate whether HMGCR splice
variants identified in this study are physiologically functional.
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Background
Human 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase (HMGCR) is the rate-limiting enzyme in
the isoprenoid/cholesterol biosynthesis pathway. The
enzyme converts HMG-CoA to mevalonate and is the
main target of commonly used lipid-lowering drugs (i.e.,
statins) [1]. Some of the major intermediates in the path-
way are used to synthesise ubiquinone, dolichol, heme A
and isoprenoid lipids [2]. The end-product, cholesterol,
is the precursor for the synthesis of crucial compounds,
such as steroid hormones, bile acid and vitamin D.
HMGCR is encoded by a single gene on chromosome
5 (5q13.3-q14). Two transcript variants are annotated
in the National Center for Biotechnology Information
(NCBI) Reference Sequence (RefSeq) database; the
canonical full-length transcript composed of 20 exons
(NM_000859.2) and an alternatively spliced variant lack-
ing exon 13 (NM_001130996.1). Additionally, exon junc-
tion microarray experiments suggest the presence of at
least three more HMGCR splice variants lacking exon 8
(AY429542), exon 18 (AY429543) and exons 17 and 18
(AY429544) [3].
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Expression of HMGCR is strictly regulated at the
transcriptional and post-transcriptional level. Cholesterol
homeostasis is maintained by HMGCR transcriptional
inhibition and enzyme modifications via negative feed-
back mechanisms (reviewed in [4]). Under sterol-depleted
conditions, such as statin treatment, HMGCR transcrip-
tion is co-ordinately activated with transcription of the
low density lipoprotein receptor and other genes in the
cholesterol biosynthetic pathway [5].
Genomic diversity is greatly expanded by the process of
alternative splicing, by which introns are removed
and exons are ligated together to form various mature
mRNA transcripts. Alternative splicing has been suggested
as another mechanism underlying HMGCR regulation
and cholesterol homeostasis [6]. An HMGCR splice vari-
ant lacking exon 13 (denoted here as HMGCRΔexon13)
was reported to have decreased enzymatic activity and to
be less sensitive to statin inhibition [3,7,8]. Exon 13
encodes parts of the catalytic domain and the statin bind-
ing site of HMGCR [9,10]. Recently, the major A allele of
a single-nucleotide polymorphism (SNP, rs3846662,
A>G) located within intron 13 of HMGCR was found to
be associated with skipping of exon 13 [7]. The relative
abundance of HMGCRΔexon13 mRNA has also been
reported to be associated with interindividual variation in
statin-mediated lipid-lowering responses [8,11]. In the
present study, nucleotide sequence database queries iden-
tified several novel HMGCR splice variants. One of these,
HMGCR-1b, shows alternative exon 1 usage, with a novel
HMGCR N-terminus predicted. We report the mRNA
levels of novel HMGCR splice variants in a variety of
healthy human tissues. Furthermore, we present the regu-
latory responses of these variants in HepG2 cells upon
statin treatment.
Methods
Bioinformatic analysis
Inspection of displayed mRNA, expressed sequence tag
(EST) and RNA sequencing (RNA-seq) tracks at the
HMGCR gene locus was performed using the Genome
Browser Database provided by the University of California,
Santa Cruz (UCSC) on human genome assembly GRCh37/
hg19 [12]. The other bioinformatic tools used were Primer3
software [13], Finch TV1.4.0 (Geospiza, Seattle, USA),
DNASTAR Lasergene 7.2 (Madison, WI, USA) and the
NCBI database of SNPs.
Cell culture and statin treatment
The HepG2 cell line (American Type Culture Collection,
Manassas, VA, USA) was grown in modified Eagle’s
minimal essential medium (MEM; ATCC) supplemented
with 10% heat inactivated fetal bovine serum (FBS)
and and 1× penicillin-streptomycin-glutamine (P/S/G)
mixture (Sigma-Aldrich, St Louis, MO, USA) in collagen
I-coated tissue culture flasks (BD Biosciences, San Jose,
CA, USA). Cells were seeded at 2 × 105 cells/mL in 12-
well collagen I-coated plates (BD Biosciences), and the
statin treatment was carried out in triplicate on the
following day. HepG2 cells were cultivated for 24 hrs in
MEM with 1× P/S/G containing 3 mg/mL of human
lipoprotein deficient serum (LPDS; Millipore, Billerica,
MA, USA), with or without 10 μM of (3 S, 5 S)-Atorvas-
tatin Sodium Salt (Toronto Research Chemicals North
York, Ontario, Canada) dissolved in water in a total vol-
ume of 1 mL. Two lymphoblastoid cell lines (GM17752
and GM20518; Coriell Institute for Medical Research,
Camden, NJ, USA) were cultured according to the man-
ufacturer’s instructions. Sequencing confirmed the CC
and AA genotypes of the rs3761740 polymorphism in
GM17752 and GM20518 cell lines, respectively. Statin
treatment was carried out as described above, except
that 5 × 105 cells/mL of each cell line were seeded into
24-well plates and treated the same day. Cell cultures
were maintained at 37°C/5% CO2.
Purification of total RNA from cells
Total RNA from HepG2 cells was isolated using an
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) by
following the protocol provided by the manufacturer.
DNase digestion with an RNase-Free DNase Set
(Qiagen) was used to ensure DNA-free RNA samples.
The RNA was eluted in 30 μL of RNase/DNase-free
water and stored at −80°C until required. RNA samples
were quantified using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE,
USA). RNA quality was assessed by microfluidic capil-
lary electrophoresis using an Agilent 2100 Bioanalyzer
and the RNA 6000 Nano Chip kit (Agilent Technologies,
Santa Clara, CA, USA). RNA samples were denatured
for 2 min at 70°C prior to cDNA synthesis.
Total RNA from human tissues
High-quality pooled RNA samples from the Human
Total Master panel II and the Human Adult Normal
Tissue panel were purchased from Clontech (Mountain
View, CA, USA) and BioCat GmbH (Heidelberg,
Germany), respectively. Ten random RNA samples were
assessed for concentration and integrity as described
above. All samples were from anonymous donors and
commercially available.
Synthesis of cDNA
The levels of mRNA expression were analysed using
total RNA from tissues (1000 ng) and cells (200 ng) in a
20 μL cDNA synthesis reaction using an Omniscript RT
Kit (Qiagen) and a mixture of 2.5 μM oligo-dT and
6.25 μM random hexamers (Applied Biosystems, Foster
City, CA, USA). Reverse transcription (RT) was performed
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at 37°C for 60 min, followed by 95°C for 5 min. The
cDNA samples were diluted 1:5 in RNase/DNase-free
water and stored at −20°C prior to use as templates for
PCR amplification. A pooled cDNA sample was obtained
by mixing an aliquot of each of the 44 undiluted cDNA
samples and a 1:10 dilution in RNase/DNase-free water.
PCR
Polymerase chain reaction (PCR) amplification of the
different first exons of HMGCR in a cDNA pool derived
from 44 human tissues (as described above) was per-
formed with HotStarTaq DNA Polymerase (Qiagen) fol-
lowing the manufacturer’s instructions Forward primers
(exon1a, 5′-GAG CGT GCG TAA GGT GAG G-3′;
exon1b, 5′-GAG AGC AGA AGG AAC GCA CA-3′;
exon1c, 5′-GAC ATG GTC CTG CAG AGT CG-3′;
and exon1d, 5′-GCA GCA TTG CAT AAA TAC TGT
CA-3′) were used in combination with a reverse primer
in exon 3 (exon3, 5′-TGT CAG AAT TAT AAT GTC
ACT GCT CAA-3′). The cycling conditions were 15 min
at 95°C, followed by 37 cycles of 30 s at 94°C, 30 s at
55°C, 1 min at 72°C and a final extension step at 72°C for
10 min. PCR products were separated on 1–3% (w/v)
agarose gels. Images were captured using a Kodak Image
Station 440CF and visualised using Kodak Molecular
Imaging Software, version 4.5 (Eastman Kodak Co., New
Haven, CT, USA). The PCR products of interest were
excised and purified using the QIAquick Gel Extraction
Kit (Qiagen) and confirmed by sequencing.
Molecular cloning
The full-length HMGCR-1b transcript was PCR ampli-
fied using a ProofStart DNA polymerase kit (Qiagen)
and a cDNA template synthesised from skin (BioCat
GmbH). The PCR mix contained 1× proof start buffer,
1× Q-solution, 0.25 U ProofStart, 5 U HotStarTaq plus
DNA polymerase, 350 mM dNTP mix, 2 μL of cDNA
and 0.4 μM forward primer (exon1b, 5′-CGC AGG
AGA GGC ACA TTT CAG-3′) and reverse primer
(exon20, 5′-GGG CTG TCT TCT TGG TGC AAG
C-3′) in a total volume of 50 μL. The cycling conditions
were 5 min at 95°C, followed by 37 cycles of 30 s at
94°C, 1 min at 55°C, 3 min at 72°C and a final extension
step at 72°C for 30 min. Purified PCR products were
cloned using the CT-GFP Fusion TOPO TA Expression
Kit (Invitrogen Corporation, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. Positive clones
were confirmed by sequencing.
Quantitative PCR (qPCR)
All qPCRs were performed on an ABI 7900HT Real-
Time PCR System in a standard 96-well format. TaqMan
hydrolysis probes (Custom TaqMan Gene Expression
Assay from Applied Biosystems) were designed for specific
gene quantification of HMGCR-1a, HMGCR-1b and
HMGCR-1c. The following TaqMan primer and probe
sets were used: 5′-CCA TGC ATT CGA AAA AGT
CTT GAC A-3′ (forward primer), 5′-GGT TCG GTG
GCC TCT AGT G-3′ (reverse primer) and the FAM-
reporter probe 5′-TCC TTG GAT CCT CCA GAT
CT-3′ for targeting the HMGCR exon 1a-exon 2 bound-
ary; 5′-AAT GGA TGT CGC ACA CAA GAG A-3′
(forward primer), 5′-CCA TGC ATT CGA AAA AGT
CTT GAC A-3′ (reverse primer), and the FAM-reporter
probe 5′-CTT GGA TCC TGC GTC TCT-3′ for target-
ing the HMGCR exon 1b-exon 2 boundary; and 5′-TTT
CTG GGC TAT ACT AAA TGT GCA TGA-3′ (forward
primer), 5′-CCA TGC ATT CGA AAA AGT CTT GAC
A-3′ (reverse primer) and the FAM-reporter probe
5′-ACA AGG ATC CAA GGA TTC-3′ for targeting the
HMGCR exon 1c-exon 2 boundary. Each qPCR mix
comprised 10 μL of TaqMan Universal PCR Master Mix,
7 μL of RNase-free water, 1 μL of TaqMan hydrolysis
probe and 2 μL of cDNA. The cycling steps were 10 min
at 95°C followed by 40 cycles of 95°C for 15 s and 60°C
for 1 min. Non-template controls were included in each
run. All qPCR experiments were performed at least in
duplicate. Samples exhibiting more than a 0.5 quan-
tification cycle (Cq) difference between the duplicates
were excluded from the relative quantification analysis.
Samples showing Cq > 35 or undetermined were set to
Cq= 38 and were considered not detectable.
Reference gene selection
The stability of 12 reference genes from Applied Biosys-
tems (see [14] for assay IDs) was checked to confirm the
reliability of gene expression results across the tissue
samples tested. Five (GAPDH, PGK1, SDHA, CTBP1,
GOLGA1) were found by geNorm [15,16] to give the
most suitable normalisation factors for quantification of
relative expression levels. For the atorvastatin treatment
experiments in HepG2 cells, the PPIA, TBP, PGK1,
ACTB, GAPDH, UBC, PPIB, and SDHA reference genes
were tested. Two reference genes, PPIA and TBP, were
found by geNorm to be the most stable and therefore
were suitable for normalisation. The mean expression
value was used for the normalisation, according to the
“ΔΔCq method” for comparing relative expression
results between treatments [17]:
ΔΔCq ¼ 2 ΔCqtreated ΔCq nontreatedð Þ
Reporter vector construction
Different regions of the human HMGCR promoter cov-
ering −1626 to +12 (relative to the annotated HMGCR
transcription start) were amplified by PCR. Genomic
DNA from the Human Variation Panels (NA07055;
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Coriell Institute for Medical Research) heterozygous for
the HMGCR promoter SNP C>A (rs3761740) were
used as PCR templates. The PCR primers were: 5′-AGC
GGT ACC GCC ATT TAC ACT AAT GGG TAA AT-3′
(forward primer) and 5′-AGT AAG CTT GAC CAA
TAA GAG AGG ATC GTT CG-3′ (reverse primer) for
construction of the reporter vector 1 (−559 to +12);
5′-AGC GGT ACC AAT GGG TAG GCA TAT CCA
AGG-3′ (forward primer) and 5′-AGT AAG CTT CTG
CGT CTT CTG TGC GTT C-3′ (reverse primer) for
construction of reporter vectors 2 and 3 (−1009 to
−615); and 5′-AGC GGT ACC TTG ACA AGG CTG
CTA AGA GAA CA-3′ (forward primer) for construc-
tion of reporter vectors 4 and 5 (−1626 to −615) in com-
bination with the same reverse primer used for reporter
vectors 2 and 3. Restriction sites for KpnI and HindIII
are underlined in the forward and reverse primer
sequences, respectively. The PCR was performed using a
Phusion High-Fidelity PCR kit (Finnzymes Oy, Espoo,
Finland) according to the manufacturer’s instructions.
Cycling conditions were as follows: 30 s at 98°C, fol-
lowed by 35 cycles of 10 s at 98°C, 30 s at 63°C, 1 min
at 72°C and a final extension step of 10 min at 72°C.
The PCR-amplified promoter regions were cloned
into the KpnI and HindIII restriction sites of the pro-
moterless firefly luciferase vector pGL.4.10 (Promega,
Madison, WI, USA).
Transfection and reporter gene assay
HepG2 cells were seeded on the day prior to transfection
at 1.25 × 105 cells/mL into a 24-well collagen I-coated
plate (BD Biosciences) in 0.5 mL of culture medium. For
each transfection, 485 ng of the firefly luciferase empty
control vector (pGL4.10) or a test reporter vector was
co-transfected with 15 ng of renilla luciferase internal
control vector (pGL4.73) to normalise for transfection
efficiency. Transfection was carried out in triplicate
using 1.25 μL of FuGENE HD (Roche Diagnostics Cor-
poration, Indianapolis, IN, USA) reagent per well. Cells
were washed with 1 mL 1× phosphate-buffered saline at
24 h post-transfection and then treated with 100 μL of
Passive Lysate Buffer supplied in the Dual-Glo luciferase
assay kit (Promega). After gentle rocking (15 min),
the lysates were assayed for luciferase activity with the
Dual-Glo luciferase assay system according to the manu-
facturer’s instructions. Firefly luciferase and renilla luci-
ferase activities were measured using the Wallac 1420
Victor™ luminometer in a 96-well Wallac B&W Isoplate™
(Perkin Elmer, Turku, Finland). Delay and measurement
times were set to 2 s and 10 s, respectively. The linear
range of light detection was determined using a dilution
series of QuantiLum Recombinant Luciferase (Promega).
Firefly luciferase activity was normalised to renilla luci-
ferase expression. Luciferase (Luc) activity induction was
calculated as fold-change according to the following
equation:
Fold change
¼ Mean Firefly=Renillað Þtest reporter vector½ 
= Mean Firefly=Renillað Þemptycontrol vector½ 
Results
Identification of HMGCR splice variants
Bioinformatic analysis and visual inspection of the
region between HMGCR exon 2 and its adjacent,
5′-flanking gene in the UCSC genome browser indicated
at least three alternative first exons, each spliced to the
constitutive exon 2 (Acc. No: AK296499, DA809145,
BX952828, designated exons 1b, 1c and 1d, respectively;
Figure 1A). Tracks of published RNA-seq data indicated
transcription of exon 1b, whereas no convincing evi-
dence was found for transcription of exons 1c and 1d.
Transcription of exons 1b and 1c was confirmed by
RT-PCR (Figure 1B) of the cDNA pool derived from 44
different tissues. Expression of the predicted exon 1d
could not be confirmed by RT-PCR in any of the investi-
gated tissues. The open reading frame of the canonical
HMGCR transcript (=888 amino acids) is maintained in
exon 1c, but sequence analysis of exon 1b predicted an
additional 20 amino acids at the N-terminus. We cloned
and sequenced HMGCR-1b (exon 1b– exon 20) and
confirmed that exons 1a and 1b were mutually exclusive.
We also found that HMGCR-1b transcripts were subject
to exon 13 skipping (HMGCR-1bΔ13) (Figure 1C). Exon
1b is potentially translated in certain primates as indi-
cated by alignment of nucleotide sequences from differ-
ent vertebrate species (Figure 1D).
Tissue distribution of HMGCR-1a, -1b and -1c
The RT-qPCR experiments showed variable levels of al-
ternative first exons of HMGCR in 36 different tissues
(Figure 2). The canonical HMGCR-1a transcript was
ubiquitously expressed at the highest levels in the
cerebellum, fetal brain, testis, skin and adrenal gland
(Figure 2A). The highest expression of HMGCR-1b
was detected in the skin, esophagus, uterine cervix and
prostate (Figure 2B). HMGCR-1b mRNA levels were
below detection levels (Cq > 35.0) in six tissues. The level
of HMGCR-1a in liver (pooled from three different
donors) was approximately two-fold higher than that of
HMGCR-1b. We observed higher HMGCR-1a expres-
sion in most of the tissues analysed with the exception
of the skin, esophagus, uterine cervix and colon, in which
the levels of HMGCR-1b were higher (approximately
1.5–2.0-fold; Figure 2D). HMGCR-1c was detectable
(Cq < 35) in only nine of the tissues analysed and was less
abundant than HMGCR-1a. The highest expression of
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HMGCR-1c was detected in the cerebellum, fetal brain,
testis and adrenal gland (Figure 1C). HMGCR-1c could
not be quantified in the skin or uterine cervix (Cq > 35),
where HMGCR-1b was relatively abundant.
Expression analysis before and after atorvastatin
treatment in HepG2 cells
HepG2 cells, a model system for cholesterol biosynthesis
studies, were treated with atorvastatin for 24 h. The
RT-qPCR experiments showed significant mRNA induc-
tion (p < 0.05) for HMGCR-1a (2.1 ± 0.2-fold (mean ± SE;
Figure 3A), HMGCR-1b (1.6 ± 0.2-fold; Figure 3B) and
HMGCR-1c (2.6 ± 0.3-fold; Figure 3C) in cells after
atorvastatin treatment compared with untreated cells.
The magnitude of induction was significantly different
between HMGCR-1a and HMGCR-1b, and between
HMGCR-1b and HMGCR-1c (p < 0.05), but not between
HMGCR-1a and HMGCR-1c (p= 0.16). The HMGCR-1c
and HMGCR-1b splice variants were less abundant
(approximately 60-fold lower) in HepG2 cells compared
with the canonical HMGCR-1a. The fact that exon 1b
was found to be approximately two-fold lower than exon
1a in the liver suggests that there are major differences
in the expression levels of these transcripts, either be-
tween different liver donors or because of cell immortal-
isation and/or an artificial cell culture environment for
the HepG2 cells.
HMGCR promoter analysis
Bioinformatics showed that exon 1b is located 35 bp up-
stream of the CpG island in the previously characterised
HMGCR promoter. We performed luciferase reporter
gene assays in HepG2 cells under various conditions to
investigate the promoter activity driving the transcrip-
tion of HMGCR-1b and the genetic influence of the pro-
moter SNP rs3761740, which is close to exon 1b. The
HMGCRA B
0.35 kb
0.30 kb
chr5:74630446-74658151
1b 1 1 1da    c    
C
0.80 kb
0.60 kb exon13CDSUTR IVS
D
Figure 1 Alternative splicing of HMGCR. (A) Genomic organisation of human HMGCR at chromosome 5q13.3. Exons are separated by introns
(IVS) and represented by white and black boxes illustrating predicted untranslated regions (UTR) and coding sequences (CDS), respectively. The
canonical exon 1a is part of the HMGCR reference sequence (NM_000859) and exons 1b, 1c and 1d are predicted from published ESTs. The red
box indicates the cassette exon 13, which is skipped in an alternative HMGCR transcript (NM_001130996). (B) Validation of exon 1a-, 1b-, 1c- and
1d-transcription by RT-PCR using exon-specific primers and a cDNA pool of 44 tissues visualised on a 3% (w/v) agarose gel. RT-PCR identified
HMGCR transcripts with different first exons. Transcription of exon 1d could not be confirmed. (C) Exon 13 (159 bp) skipping (Δexon13) of both
HMGCR-1a and HMGCR-1b identified by PCR and visualised on a 2% (w/v) agarose gel. cDNA synthesised from skin was used to amplify the
HMGCR transcripts from exons 1a and 1b, respectively, through exon 16 followed by nested PCR from exon 10 through exon 14. The existence of
HMGCR-1b Δexon13 was confirmed by cloning and sequencing. (D) Multiple sequence alignments of HMGCR exon 1b in different mammalian
species showing conservation of exon 1b only in higher primates. The alignment was created using the UCSC Genome Browser “Vertebrate
Multiz Alignment & Conservation (46 Species)” track. An in-frame start codon (ATG) is preserved in higher primates and presented as the
methionine single letter code (M). Single dashes indicate alignment gaps, and double dashes represent one or more unalignable bases in the
gap region.
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Figure 2 Expression of HMGCR-1a, -1b and -1c in various human tissues. HMGCR-1a, -1b and -1c mRNA levels were determined by RT-qPCR
in various human tissues using exon 1-specific primers. (A) HMGCR-1a, (B) HMGCR-1b (C) HMGCR-1c mRNA levels were normalised to a
tissue-dependent factor based on five reference genes and calculated as ratios relative to the highest mRNA level (reference), which was set to 1.
(D) Ratios of HMGCR-1a and HMGCR-1b mRNA levels are given on a logarithmic scale (base 2). HMGCR-1b is in low abundance compared with the
canonical HMGCR-1a in most of the analysed tissues (ratio >0), except in the skin, esophagus, uterine cervix and colon (ratio <0).
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promoter region upstream of exon 1a (reporter vector 1,
which was used as a positive control) was active under
standard culture conditions with 10% FBS (Figure 4).
The exon 1a promoter was further activated under
sterol-depleted conditions with LPDS (1.7 ± 0.2-fold) and
LPDS+ atorvastatin (3.0 ± 0.6-fold) when compared with
the activity of transfected cells cultured under standard
conditions, containing 10% FBS. The reporter vectors 2,
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Figure 3 Upregulation of HMGCR transcript variants in HepG2 cells treated with atorvastatin. HepG2 cells were incubated in culture
medium with lipoprotein deficient serum (LPDS; non-treated) and 10 μM atorvastatin + LPDS for 24 h (treated). The mRNA levels of (A) HMGCR-1a
(B) HMGCR-1b and (C) HMGCR-1c were measured by RT-qPCR using exon1-specific primers and a set of validated reference genes for
normalisation. The results are shown as the mean fold-change compared with mRNA levels in non-treated cells. Error bars indicate standard
errors (± S.E), n = 5. *Statistically significant differences between non-treated and treated (p< 0.05) were determined using Student’s t-test. †The
magnitude of statin-induced upregulation of HMGCR-1b was significantly lower (p< 0.05) than that of HMGCR-1a and HMGCR-1c, respectively, as
determined by a paired-sample Student’s t-test.
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Figure 4 Promoter activities of the canonical HMGCR-1a and the putative HMGCR-1b promoter in HepG2 cells. Solid bars illustrate
different sizes of genomic sequences upstream of exon 1a and exon 1b that were cloned into pGL4.10. The HMGCR promoter SNP (C> A,
rs3761740) is highlighted in red and represented by both alleles. Luciferase activity was measured in the lysates of transfected cells incubated for
24 h in fetal bovine serum (FBS), lipoprotein-deficient serum (LPDS) or LPDS with 10 μM atorvastatin (Atv). The promoter activity is shown as the
mean fold-change in firefly luciferase activity relative to the mean firefly luciferase activity of the empty pGL4.10 vector, which was set to 1 after
correction for transfection efficiency using Renilla luciferase activity. The results are the mean of three independent experiments performed in
triplicate. Error bars indicate standard errors (± S.E).
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3, 4 and 5, each containing genomic fragments upstream
of exon 1b, exhibited low promoter activities that were
not induced by sterol depletion (LPDS), or by higher
degrees of sterol depletion (LPDS + atorvastatin). The
minor A allele of the promoter SNP C>A (rs3761740)
did not affect the promoter activity of exon 1b when
compared with the major allele C reporter vector. The
effect of the promoter SNP C>A (rs3761740) on
HMGCR exons 1a and 1b mRNA levels was investigated
after atorvastatin treatment in two different lymphoblas-
toid cell lines homozygous for either allele. The RT-
qPCR experiments (n = 5) showed similar induction of
HMGCR-1b mRNA levels after atorvastatin treatment in
both lymphoblastoid cell lines, independent of the allelic
status. HMGCR-1b was induced 1.2 ± 0.1-fold (mean ±
SE) and 1.3 ± 0.1-fold in cells with the major CC and the
minor AA genotype of rs3761740, respectively. The
magnitude of induction was not significantly different
between the two different cell lines. The canonical
HMGCR-1a transcript was upregulated 1.7 ± 0.1-fold
in both lymphoblastoid cell lines after atorvastatin
treatment.
Discussion
HMGCR is the key enzyme in the cholesterol bio-
synthesis pathway and is the major target of cholesterol-
lowering statin drugs. Here, we demonstrate the
existence of alternative exon 1 usage in human HMGCR,
resulting in several novel transcript variants. One of
these, HMGCR-1b, encodes a novel N-terminus which
potentially extends the membrane domain by 20 amino
acids compared with the canonical sequence. The
canonical HMGCR protein is composed of 888 amino
acids with a regulatory, sterol-sensing transmembrane
domain (residues 10 – 339), a flexible linker (residues
340 – 449) and a C-terminal catalytic region (residues
450 – 888) [18]. We studied HMGCR-1b at the genomic
and transcriptional levels. Whether the translation
machinery actually recognises the first AUG as a start
codon to produce a protein with 20 additional amino
acids in the membrane domain remains to be deter-
mined. Unfortunately, initial experiments using rabbit
antibodies raised against the novel N-terminus of the
predicted HMGCR-1b polypeptide exhibited non-specific
binding (data not shown).
In mammalian genomes, only one gene encodes the
HMGCR enzyme, which mainly resides in the mem-
brane of the endoplasmic reticulum [19,20]. A minor
fraction (approximately 5%) of the reductase activity has
been demonstrated in rat liver [21-23] and mouse brain
[24] to be localised in the matrix of peroxisomes. The
signal that targets HMGCR to peroxisomes has not yet
been determined. The HMGCR-1b transcript identified
in this study is remarkably less abundant than the
canonical HMGCR-1a in most of the tissues analysed,
and it is tempting to speculate that exon 1b might
encode the missing HMGCR peroxisomal targeting in-
formation [25]. However, bioinformatic analysis of the
N-terminus of the hypothetical HMGCR-1b protein did
not reveal any peroxisomal targeting signals (data not
shown).
Our finding that HMGCR generates multiple 5′ end
transcripts is not unusual in the human genome [26].
There are numerous other examples in the literature.
The gene locus encoding the uridine diphosphate–
glucuronosyltransferase 1 family contains several differ-
ent coding first exons, which generate at least nine
different transcripts encoding various isozymes with
unique N-termini and substrate specificities [12]. An-
other example is the CYP19A1 gene encoding aroma-
tase, the rate-limiting enzyme of estrogen biosynthesis,
which contains alternative non-coding first exons affect-
ing RNA stability and aromatase levels in tissues. Differ-
ential use of non-coding first exons is suggested to be an
important mechanism of post-transcriptional regulation
of aromatase gene expression [27].
Whether an alternatively spliced variant is functional
is considered in the context of tissue-specific expression
and conservation in most studies [28]. The mRNA levels
for the alternative HMGCR-1b splice variant were more
abundant than the canonical HMGCR-1a levels in epi-
thelial tissues, such as skin. Skin is one of the major sites
for cholesterol production in the body [29], where
HMGCR activity and cholesterol synthesis are crucial
for hindering fluid loss from the body by maintaining
the permeability barrier [30]. In addition, the production
of non-cholesterol isoprenoid intermediates by HMGCR
has been reported to be important during acute wound
healing [31]. Sequence alignment of HMGCR-1b did not
show conservation of the open reading frame in all ter-
restrial animals. Therefore, it remains to be determined
whether the HMGCR-1b splice variant exerts an epithe-
lial or skin-specific role in sustaining the epithelial bar-
rier function in certain primates.
Tissue-specific gene expression may be regulated via
differential gene promoter activity [32]. The weak pro-
moter activity of the genomic region upstream of exon
1b is in accordance with the rather low, basal mRNA
expression level of exon 1b found in HepG2 cells. Unex-
pectedly, the alternative promoter activity in the reporter
assay was not induced by sterol depletion, although
there was an increase in the HMGCR-1b mRNA level in
HepG2 cells. Based on these results, the increased
HMGCR-1b mRNA level due to sterol depletion in
HepG2 cells most likely results from post-transcriptional
regulation and/or regulatory promoter DNA sequences
not captured in our reporter vector constructs. More-
over, previous studies have identified a functional C>A
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SNP (rs3761740) in the HMGCR promoter [23,33].
Keller et al. identified a sterol regulatory element (SRE)
in this position. They found that the minor A allele was
more responsive to the overexpression of sterol regula-
tory element-binding protein 2, compared with the
major C allele [33]. In our experiments, this promoter
SNP, which is close to the transcription start of exon 1b,
did not contribute significantly to the proximal pro-
moter activity or mRNA level of HMGCR-1b or to the
transcription of the canonical HMGCR-1a variant upon
sterol depletion.
Approximately half of human genes are predicted to
have alternative promoters [34]. A comparative study of
different promoter features in human and mouse genes
reported a distinct class of “non-conserved” promoters
in humans [35]. Alternative promoters differ from the
major promoter in their responsiveness to a specific
condition, resulting in different expression levels in tis-
sues or developmental stages and thereby increasing the
flexibility of gene expression. Given that the putative
HMGCR-1b promoter identified in our study (i) exhibits
a different response to statin treatment compared with
the canonical HMGCR promoter, (ii) is of minor usage,
(iii) is lacking CpG islands, and (iv) that the HMGCR-1b
transcript shows an expression pattern distinct from that
of HMGCR-1a, it seems likely that the HMGCR-1b pro-
moter represents an alternative, non-conserved HMGCR
promoter that contributes to the expressional diversity
of this gene.
With respect to HMGCR-1a, we also found that exon
13, which encodes amino acids in the catalytic region, is
a cassette exon in the HMGCR-1b transcript, meaning
that this exon is either included (HMGCR-1b) or skipped
(HMGCR-1bΔ13). The catalytically active HMGCR is
formed as a tetramer with two dimers [10]. Medina et al.
have proposed that the inactive HMGCR lacking exon
13 modulates the HMGCR enzyme activity by being part
of the catalytically active tetramer and thereby reducing
its total enzyme activity [11]. Further studies are needed
to clarify whether the delta-exon 13 variant of the
HMGCR-1b transcript also contributes to HMGCR en-
zyme activity modulation and statin response.
Conclusions
We have shown that human HMGCR uses different first
exons to produce multiple alternatively spliced variants,
thereby contributing to increased transcriptional com-
plexity. We have designated these splice variants
HMGCR-1a, HMGCR-1b and HMGCR-1c. The novel
HMGCR exon 1 (HMGCR-1b) we identified contains an
in-frame ATG translational start codon predicting an
extended N-terminus of HMGCR. Moreover, we showed
that this transcript variant is differentially expressed
in a wide variety of healthy human tissues, and that its
mRNA levels are regulated upon statin treatment.
Further studies are needed to elucidate potential physio-
logical roles of differential first exon usage in HMGCR.
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